Open Mini-Flank Partial Nephrectomy: An Essential Contemporary Operation

Paul Russo, Roy Mano
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Secondary to the widespread use of the modern imaging techniques of computed tomography, magnetic resonance imaging, and ultrasound, 70% of renal tumors today are detected incidentally with a median tumor size of less than 4 cm. Twenty years ago, all renal tumors, regardless of size were treated with radical nephrectomy (RN). Elective partial nephrectomy (PN) has emerged as the treatment of choice for small renal tumors. The basis of this paradigm shift is three major factors: (1) cancer specific survival is equivalent for T1 tumors (7 cm or less) whether treated by PN or RN; (2) approximately 45% of renal tumors have indolent or benign pathology; and (3) PN prevents or delays the onset of chronic kidney disease, a condition associated with increased cardiovascular morbidity and mortality. Although PN can be technically demanding and associated with potential complications of bleeding, infection, and urinary fistula, the patient derived benefits of this operation far outweigh the risks. We have developed a "mini-flank" open surgical approach that is highly effective and, coupled with rapid recovery postoperative care pathways associated with a 2-day length of hospital stay.

Keywords: Chronic kidney failure; Methods; Nephrectomy

INTRODUCTION

In the last 20 years partial nephrectomy (PN) has emerged as a critical operation for the treatment of renal cortical tumors. Once reserved only for the essential indications of tumors in an anatomically or functionally solitary kidney, today PN can effectively achieve the same local tumor control as radical nephrectomy (RN) while maximally preserving renal function and preventing or worsening pre-existing chronic kidney disease (CKD). The realization that approximately 70% of renal tumors today are detected incidentally with a median size of less than 4 cm and ultimately 45% will have indolent or benign final pathology has further expanded the utilization of PN. The historical use of RN for all renal tumors regardless of size must now be considered obsolete. We have replaced the large and painful eleventh rib flank incision with a mini-flank surgical incision which, when coupled with our rapid recovery clinical pathway, is highly effective for PN and leads to an average 2-day hospital length of stay. This approach is an excellent alternative to the expensive and technically complex minimally invasive approaches (laparoscopic and robotic assisted laparoscopic). It is the purpose of this manuscript to describe in detail our clinical approach to the patient eligible for PN, the intraoperative surgical details, and the management of perioperative complications.

TRANSITION FROM RADICAL TO PARTIAL NEPHRECTOMY

Radical surgical resection of all tumors in the tradition of Halsted was the uniform oncological opinion for the first 70 years of the 20th century. This approach transitioned to organ (i.e., breast) and limb (i.e., sarcoma) sparing operations that provided the same outcomes as their more radical counterparts without severe disability. RN for large, symptomatic, and often metastatic kidney tumors was popularized in the 1960's and is still utilized today in ap-
proximately 30% of kidney tumor patients [1-11]. PN was rarely performed and only in patients with tumors in an anatomic or functionally solitary kidney or for those with bilateral synchronous tumors. Advances in complex stone surgery (anatomic kidney splits, hilar clamping, ice slush, collecting system repair), trauma surgery (renorrhaphy, proximal renal hilar control, vascular repair), and kidney donor transplantation (renoprotective solutions) set the stage for the development of controlled open PN [12-17]. The rapid development of the modern imaging modalities of ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), often ordered for nonspecific abdominal or musculoskeletal complaints, lead to the detection of the small, asymptomatic renal mass [18], which today accounts for 70% of all newly diagnosed renal tumors with a median tumor size of < 4 cm (T1a).

Approximately 20% of these tumors are benign neoplasms (i.e., oncocytoma, fat poor angiomylipoma), 25% are indolent malignancies with limited metastatic potential (i.e., papillary type 1, chromophobe) and 54% are the malignant clear cell carcinoma but at the T1 size (< 7 cm), metastasis would be realized in less than 10% of patients [18], factors which taken together lead to the expansion of elective PN in the early 1990’s [19].

Initially, elective PN was restricted to tumors of 4 cm or less and reports indicated excellent rates of local tumor control and disease-free survival rates of greater than 90% [19-21]. Intraoperative US allowed surgeons to approach more complex and often impalpable endophytic, renal sinus, multifocal, and renal hilar tumors with PN [22]. Reports from the United States and abroad indicated oncological equivalency of PN to RN for tumors of 4 cm or less [23-26]. Expansion of PN for larger (4-7 cm) or higher stage tumors (T2, T3a) located in amenable positions also did not appear to compromise oncological outcomes [27-33].

NEW CONCERNS REGARDING RENAL FUNCTIONAL PRESERVATION

Based largely on the renal donor transplant experience, it was thought that RN, even for small kidney tumors, would not compromise the patient’s long term renal function [34]. However, unlike the carefully selected, young, and healthy kidney donors, kidney tumor patients were on average 25 years older and many suffered from common medical diseases that can affect baseline kidney function such as diabetes, hypertension, and vasculopathy [35,36]. The aging process itself is associated with glomerular atrophy and reduced glomerular filtration rates (GFRs) [37]. Reports appeared describing an elevated postoperative serum creatinine and proteinuria in RN patients compared to PN patients [38,39] and raised concerns that some RN patients were iatrogenically developing a new clinical entity, CKD, described as a GFR of less than 60 mL/min/1.73 m². CKD affects over 20 million Americans [40,41] and is associated with higher rates of hospitalization, adverse cardiovascular events, and worse overall survival [42]. Using formulas to estimate GFR (eGFR) [43], it was reported that 26% of patients prior to kidney surgery had pre-existing CKD despite a serum creatinine within normal limits and that RN was associated with the causation of CKD or worsening of pre-existing CKD [44]. RN induced CKD also increased the likelihood of adverse cardiovascular events and worse overall survival [45-48].

Despite the encouragement for PN for small renal masses by the American Urologic Association (AUA) Renal Mass Guideline Committee [49], RN remains over-utilized in the United States and abroad [50,51], particularly in elderly patients and women [52]. This underutilization is likely due to a combination of factors including the introduction of minimally invasive RN, a lack of training in open kidney surgery, and a lack of appreciation for the deleterious renal functional impact of RN. Today, Guidelines Committees recommend PN for all renal tumors < 7 cm when technically feasible [49,53].

PARTIAL NEPHRECTOMY: INDICATIONS, PREOPERATIVE ASSESSMENT AND SURGICAL PLANNING

An absolute indication for PN is considered in patients with a tumor in a functional or anatomical solitary kidney. A relative indication for PN is in patients with underlying medical conditions such that RN of the tumor bearing kidney would cause severe renal insufficiency. Elective PN is in patients undergoing resection of kidney tumor in the presence of a healthy contralateral kidney. Preoperative assessment begins with a careful history with a special emphasis on medical comorbidities affecting the cardiovascular and renal function, including cigarette smoking, hypertension, diabetes, and coronary artery disease, and a thorough physical examination. Correctable and potentially life threatening cardiovascular disease should be addressed (i.e., carotid endarectomy, coronary revascularization) prior to PN. A baseline calculation of eGFR should be done using the following web link for the modification of diet in renal disease or CKD-epi equation (http://www.nephbr. com/MRDR_GFR.cgi). Preoperative renal protocol CT imaging must have non contrast views in search of microscopic fat or pseudo enhancement with volume averaging to exclude benign angiomyolipoma and hemorrhagic cyst which could warrant nonoperative management [54]. A contrast enhanced study (MRI, CT or renal perfusion/excretion nuclear scan) is required to document bilateral renal function. Renal US with Doppler imaging is an effective way to assess the lesion for vascular flow [55], can characterize cystic lesions, and serve as a template for intraoperative US in order to locate small, impalpable subcortical renal tumors [22].

Although controversy surrounds the routine use of preoperative renal biopsy for renal tumor patients because of concerns for a high rate of nondiagnostic tests and low specificity [56], improved technique and specimen evaluation, have led to improved accuracy and enhanced ability to diag-
nose tumor histological sub type [57]. We selectively consider tumor biopsy when this information may dramatically change management if, for example, a renal lymphoma is considered. We do not biopsy tumors of elderly, co-morbidly ill or frail individuals with small renal tumors and limited life expectancy since the information does not change nonoperative management plans.

Prior to the operation, an in depth discussion with the patient, describing the anticipated degree of surgical difficulty in completing a PN, the renal functional result, and a full description of potential complications including bleeding, infection, urinary fistula, the need for a prolonged perinephric drainage, and conversion to RN, if for technical reasons, a PN cannot be executed [58]. A preoperative nomogram is reassuring patients with small renal masses that a favorable long term prognosis is achievable with an effective resection [59]. A nephrometry scoring system (R.E.N.A.L) can categorize the degree of surgical difficulty for a planned PN [60]. The likelihood of a subsequent ipsi-lateral (<5%) or contra lateral (<5%) tumor recurrence in a patient's lifetime and the need for lifetime kidney imaging is discussed. For elderly patients with serious medical comorbidities and a small renal mass, active surveillance is the preferred alternative approach to PN since the vast majority of patients will not experience renal tumor progression in their remaining lifetimes and will die of competing causes [61,62].

The anticipated tempo of the hospital stay and postoperative recovery are described. The importance of walking on the first postoperative day (14 laps around the floor is a mile) to prevent deep venous thrombosis and deep breathing and incentive spirometry to prevent atelectasis and pneumonia is stressed. We rapidly progress patients to a regular diet with conversion to oral pain medication, and continued vigorous walking by the second day. The vast majority of patients are discharged on the second post op day. This regimen of vigorous walking continues at home with a switch to over the counter pain medications as soon as possible. We encourage 3 protein rich meals per day, continued walking at least 30 minutes twice per day with avoidance of heavy lifting for 3 months.

**TECHNICAL FEATURES OF OPEN PARTIAL NEPHRECTOMY: SUPRA 11TH RIB MINI-FLANK SURGICAL INCISION**

The traditional eleventh rib flank incision provided wide exposure but patients complained of significant postoperative pain, prolonged recovery, and for up to 50%, an uncomfortable and unsightly flank bulge usually caused by denervated muscle [63] often with associated paresthesias and neuralgic pain. For the surgeon, rib resection and closure of this large incision also added significant operating time. These troublesome wound difficulties were major drivers for the development of laparoscopic RN for small renal tumors and a normal contra lateral kidney in the late 1990's.

The "mini-flank" supra eleventh rib incision was developed as an effective alternative to this flank incision or laparoscopic RN [64]. With the patient in the standard flank position an 8–10 cm extraperitoneal incision is made between the bed of the 10th and 11th ribs (Fig. 1). Intercostal ligaments are sharply divided allowing for further separation of the ribs and rapid exposure to the retroperitoneum without rib resection (Fig. 2). The latissimus dorsi, external oblique and internal oblique muscles are transected and the transversus abdominus is divided in the direction of its fibers while preserving the intercostal neurovascular bundle. Using blunt dissection, the peritoneal cavity is mobilized medially, the perinephric soft tissues laterally, and the diaphragmatic fibers and pleural superiorly. A small incision in the plane between the soft tissues overlying the psoas muscle and Gerota’s fascia is then bluntly developed creating a flap of peritoneum that is retracted medially and

---

**FIG. 1.** “Mini-flank” surgical incision—8- to 10-cm extraperitoneal incision between the bed of the 10th and 11th rib.

**FIG. 2.** Intercostal ligaments are cut allowing more space between ribs and easy access to retroperitoneum.
exposes the kidney, ureter, and ipsilateral great vessel (vena cava on the right, aorta on the left). The Bookwalter retractor (Codman and Shurtleff Inc., Raynham, MA, USA) is placed using the bladder blade to medially retract the 10th rib and peritoneal flap superior medially which allows the kidney and perinephric soft tissues to move caudally into the wound. The short right-angle blade retracts the 11th rib laterally. Following blunt dissection of the intestinal contents, deeper malleable blades are placed to expose the great vessels. The ureter is isolated with a yellow vessel loop (Fig. 3) and division of lymphatic channels and soft tissues allow isolation of the renal artery and vein with red and blue vessel loops respectively (Fig. 4). We do not perform mass renal pedicle clamping with vascular clamps during cold ischemia. On the left side, the gonadal and adrenal veins may be ligated and divided to liberate the sometimes tethered renal vein to allow enhanced upward lifting of the kidney and improved access to the renal artery. The upward mobilization of the kidney decreases venous bleeding later during the tumor resection and facilitates identification and repair of rents in renal sinus veins. The upper pole of the kidney is separated from the adrenal using blunt dissection and perforating vessels are ligated and divided with the Ligasure (Covidien, Mansfield, MA, USA).

Palpation and visual and intraoperative US inspection of the renal surface is performed in order to confirm the location and depth of the tumor, identify any satellite lesions, and identify any branch renal vein or collecting system tumor invasion [22]. A polar or segmental artery may feed the exact tumor bearing area of the kidney and "regional ischemia" can be applied by placing a bulldog clamp on that artery allowing tumor resection while the rest of the kidney is normally perfused. For a purely exophytic tumor or a tumor in a patient with significant underlying CKD, resection of the tumor without renal artery occlusion is performed by gently applying a straight Satinsky clamp to the healthy kidney to allow for tumor resection and reconstruction in this alternative form of "regional ischemia" (Fig. 5). For other patients with large, endophytic, or perihilar tumors that require renal artery occlusion with a bulldog clamp, renal protective measures, including mannitol infusion (12.5 g/200 mL of normal saline) given 30 minutes prior to clamping and ice slush, are routinely used. It is unnecessary to place the kidney in a plastic bag prior to applying ice slush since the small surgical mini-flank incision does not cause significant hypothermia. We always apply ice slush hypothermia if renal artery occlusion is required and see no rationale in open PN for using warm ischemia alone. Following isolation of the tumor and its peritumoral fat, the renal cortex is scored with a 1-cm margin using the electrocautery and scissor dissection is utilized within the renal parenchymal plane (pink kidney tissue) (Fig. 6) with care not to get too close to the renal tumor's pseudo capsule (yellowish/golden tissue for conventional clear cell, brown-
ish for oncocytoma, grayish for chromophobe tumors, yellowish/tan for papillary tumors). If dissection is too close to the tumor, readjustment to a deeper plane of dissection is made. We do not “enucleate” the tumor within its pseudo-capsule. As the PN proceeds, 3-0 and 4-0 absorbable sutures are used to separately close any open small veins, arteries, and breaches in the collecting system that are encountered (Fig. 7). A search for venous bleeding can be accomplished by simply dropping the kidney into the wound (closer to the central venous pressure) and then raising it again. Deep suturing of the renal sinus is avoided because of concerns for iatrogenic a-v fistula or pseudo aneurysm formation and delayed bleeding events. The cut renal cortex is coagulated using the argon beam coagulator (ABC; Conmed Co., Utica, NY, USA) (Fig. 8). The surgical specimen is inspected to be certain there is a rim of surrounding renal and soft tissue and no fractures in the resection margin. The deep tumor surgical margin is marked with a silk suture to orient the specimen and then is delivered to the pathology department in sterile condition for a frozen section. Although the final pathology may take up to a week to complete, the frozen section can provide immediate reassurance to the surgeon that the resection was complete. Endophytic and renal sinus based tumors are especially challenging to locate and require correlation with pre-operative CT and intraoperative US. Renal sinus tumors can emanate from the renal cortex facing the renal sinus and be attached by a small area of the cortex and otherwise float freely within the sinus without invasion of vascular or collecting system elements. The renal sinus can be accessed through a horizontal cortical incision in the avascular plane (Brodel's line). The tumor is identified on its lateral border and circumferentially dissected with a rim of surrounding cortex. Penfield or Cobb dissectors are used to gently lift the tumor out of the sinus with the final dissection of the actual renal cortical attachment performed sharply. The deep renal cortical attachment is marked with a silk suture as the deep margin and submitted to orient the specimen for pathologist. Surprisingly little collecting system reconstruction is required in many renal sinus tumor resections. During reconstruction within the sinus, care is taken to include renal papilla with a corresponding calyx and not occlude a calyx during suture repair that can lead to protracted leaks and or calyceal diverticuli.

The resection cavity is filled with the hemostatic agents FloSeal (Baxter, Deerfield, IL, USA) and Surgicel (Johnson and Johnson, New Brunswick, NJ, USA) along with any available perinephric fat (Fig. 9). The renal capsule is then reapproximated using 0 chromic blunt tipped liver sutures pledgeted with Surgicel to prevent tearing of the renal cortical capsule and bleeding. The renal artery is unclamped and gentle pressure over resection bed is applied for 3–5 minutes. If no bleeding is observed and the collecting system was entering, a closed suction Jackson-Pratt drain (Allegiance Healthcare, McGaw Park, IL, USA) is placed.
through a separate stab wound in the retroperitoneal space posterior to the kidney. For exophytic tumors excised completely without entry into collecting system, the drain can be omitted. If venous oozing from the resection bed persists, another 5-minute period of gentle compression is applied. However, if brisk red arterial bleeding is observed careful inspection of the bed by cutting one or more liver sutures and ligation of any arterial bleeders is performed. Reclamping of the renal artery is avoided to prevent renal reperfusion injury. The surgical incision is closed in 2 layers using #1 polydioxanone and the skin reapproximated using 4-0 subcuticular absorbable sutures fashion (Fig. 10).

In the first report of 167 consecutive patients undergoing open mini-flank PN (n=133) or RN (n=34) from 2000–2003, excellent kidney exposure, decreased intraoperative estimated blood loss (EBL) (mean, 375 mL) and length of stay (mean, 4.5 days), and improved cosmetic results compared to traditional open techniques were obtained. After 18 months of follow-up, 3.6% of patients reported a bulge (no hernia but muscular atony) at the incision site, and 1 patient was diagnosed with an incisional hernia requiring surgical intervention [64]. In an update of 280 additional cases of open PNs, the median length of stay decreased further to 4 days, mean EBL was 300 mL, and a flank bulge was reported in only 1.8% of patients [65]. Muscle atony/bulge at the incision site without hernia is disconcerting for the patient and can be ameliorated or improved completely by exercises that twist the upper torso and core muscles (using an exercise bar, broom, or golf club). For the rare flank hernia, repair with synthetic mesh is more effective than primary closure which is likely to lead to recurrent hernia. With the advent of clinical post operative pathways emphasizing early ambulation, progression to regular diet and early switch to oral pain medications, length of stay for PN has been further reduced to 2.6 days [66].

**COMPLEX APPLICATIONS OF PARTIAL NEPHRECTOMY**

A challenging referral for PN, which in former years would have been automatic RN, are sporadic and hereditary bilateral and multifocal tumors, which have histological concordance in approximately 70% of cases and require careful surgical planning [67-70]. We approach the kidney with the largest tumor burden first since it carries the greater oncological threat [71]. The notion of performing the smaller PN first in order to “support” the larger contralateral tumor bearing kidney is no longer applicable since both can now usually be approached by PN. If the pathology of the larger is an indolent tumor with limited or no metastatic potential, such as renal oncocytosis or multifocal chromophobe renal cancer, a strong case for nonoperative management with careful observation alone for the contralateral renal tumor can be made. A careful balance between achieving local tumor control and maintaining renal function for as long as possible is paramount. In patients with diffuse multifocal tumors, such as renal oncocytosis [72] hereditary papillary renal cancer, or tuberous sclerosis, managed by long term surveillance of a tumor bearing kidney, eventual renal failure usually ensues, due to both macroscopic and microscopic disease progression and destruction of functioning glomeruli. Once the patient adjusts to dialysis, plans for completion RN of the nonfunctional kidney tumor bearing (or kidneys) can be made.

Multifocal tumors, many of which are minute in size, require careful inspection of the entire renal cortical surface along with intraoperative US to detect. As many of the minute tumors as possible are resected sharply either with fine scissors or a 15 scalpel blade with hemostasis obtained using the ABC. Larger multifocal tumors may require formal PN using cold ischemia [73]. During the resection of centrally located, hilar and perihilar tumors abutting prox-
imal major renal arteries and veins, a complete resection, even if the surgical margin is close, should be attempted because a microscopically positive surgical margin does not translate into a local tumor recurrence or worse cancer specific survival [74]. For patients with a renal tumor in a solitary kidney, PN can achieve the dual goals of local tumor control and preservation of renal function. When prolonged renal artery ischemia and postoperative acute tubular necrosis is anticipated, a preoperative renal medicine consult and placement of a tunneled subclavian dialysis catheter is prudent [75-77] in case postoperative hemodialysis is required.

During PN an intrarenal muscular branched vein tumor thrombus may be encountered. This finding is associated with a worse prognosis than previously appreciated [78], yet PN can be done utilizing basic vascular surgical principles of proximal and distal vascular control and milking the thrombus back from the vein before dividing it. Similarly, with extension of a renal tumor into the collecting system [79], reconstructive urology principles, up to and including a pyelooplasty are utilized following the complete excision. Care must be taken during the reconstruction not to exclude a papilla from the renal calyceal system which can lead to a prolonged urinary fistula in the absence of retrograde pyelogram evidence of urinary extravasation. Most such leaks close spontaneously but may take weeks or months to do so. We generally do not place indwelling ureteral stents after collecting system repairs since postoperative urinary fistula can be accentuated by reflux of urine from the contralateral kidney. In the rare and difficult circumstance of resection of a tumor involving the majority of a low capacity intrarenal pelvis where pyelooplasty is no longer an option, closure of the proximal renal pelvis with ureteral calycostomy can achieve proper drainage from the kidney. In this case we place a double J ureteral stent and a closed suction drain.

For patients with recurrent sporadic or hereditary renal tumors following a prior PN, re-do PN can be difficult due to scar tissue involving the renal hilum and is associated with greater operative time, blood loss, and more complications. Meticulous dissection around the renal hilum can lead to a successful repeat PN in the vast majority of cases [80]. Treatment failures following either percutaneous or laparoscopic thermal ablation are now being referred for salvage PN. If the residual lesions are small and the patient is elderly, frail, or comorbidly ill, we recommend active surveillance which likely would have been our preference over thermal ablation initially. If the patient is young and otherwise well, PN is attempted. Patients are forewarned that PN may be unsuccessful due to extensive fibrosis and scarring with and conversion to RN a real possibility [81,82].

Medical oncologists may refer patients with metastatic renal cancer whose primary tumor is amenable to a cytoreductive PN. For patients with compromised renal function, PN makes sense, however, if the patient has sufficient renal functional reserve, a strong case can be made for a cytoreductive RN to avoid potential postoperative wound complications associated with the targeted agents that could delay the systemic chemotherapy. Long-term concerns for renal functional decline and potential late cardiovascular morbidity may not be as relevant in this patient population with a generally poor overall prognosis [83-85].

**COMPICATIONS OF OPEN PARTIAL NEPHRECTOMY**

Complications related to PN generally fall in the three major categories of urinary fistula, bleeding, and infection. With more complex PN being performed, more complications will be encountered. If PN is performed without entry into the collecting system, urinary fistula is unlikely whereas for those tumors that are endophytic or within the renal sinus, postoperative urinary leakage is an expectation rather than complication. Variable definitions of urinary fistula in the literature (i.e., urinary leak for 2 days, 1 week, 2 weeks) can create confusion. When Memorial Sloan Kettering Cancer Center (MSKCC) investigators compared PN to RN and assessed complications with a graded scale, PN was not associated with more complications compared to RN but PN did have more procedure related complications (9% vs. 3%) due mainly to urinary fistula with reintervention rates of 2.5% for PN vs. 0.6% vs. RN. All but one reintervention involved endoscopic stents or placement of a percutaneous drain. Multivariate analysis indicated that operative time and solitary kidney were significantly associated with procedure related complications of PN [86]. Northwestern investigators analyzed 127 consecutive PN and reported urinary fistula rate of 13.3% with larger, endophytic tumors and those requiring collecting system repair more likely to have a prolonged leak [87]. MSKCC investigators analyzed 1,118 PN and defined persistent urinary leak as that lasting greater than 2 weeks or occurring in a patient that re-presents after drain removal with an urinoma requiring percutaneous drainage. Fifty-two patients developed a postoperative urinary fistula (4.4%) with persistent leak accounting for 4% and delayed fistula presentation accounting for 0.4% of cases. Factors associated with urine leak were larger tumors (3.5 cm vs. 2.6 cm), more blood loss (400 mL vs. 300 mL), and longer ischemia time (50 minutes vs. 39 minutes). Overall, 36 patients (69%) had resolution of the fistula without intervention while 16 patients (31%) underwent a stent (n=8) and another drain (n=2). No patient required a nephrectomy to manage the fistula [88]. Although most urologists use closed suction drains when necessary, there is no real data that they are any more effective than Penrose drains [89]. In the unfortunate circumstance of persistent leaks over 6-8 weeks despite good nutritional support, a cystoscopy and retrograde pyelogram should be done to exclude a distal ureteral obstruction (stenosis or ureteral kink) or injury. A disconcerting finding on such a study is a normal pyelocalyceal system yet persistent urinary drainage which indicates an excluded renal papilla with-
out a corresponding calyx. The leak may take several months to resolve until that papilla is no longer functional. If a PN is performed and no elements of the collecting system are entered, it is perfectly safe to complete the operation without the placement of a drain which will alleviate drain related patient discomfort and decrease the likelihood of a drain related nosocomial infection [90].

Pseudo aneurysm or iatrogenic arterial venous fistula forms when surgical repair of vascular rents fuses arteries and veins with direct communication developing between the two. On rare occasions, a palpable thrill can be noticed over the resection site at the end of a PN. In this case, immediate re-exploration of the surgical bed with ligation of the communicating vessels or completion RN is performed. These can present with delayed postoperative bleeding, perinephric hematoma with pain, ureteral colic, gross hematuria, hypotension, flank mass, or flank discoloration from dissecting blood. Following appropriate resuscitation, CT renal protocol is performed which will reveal arterial contrast pooling with or without perinephric hematoma, a finding which should initiate an urgent request for selective renal artery angiogram and coil embolization. The interventional radiologist should make every effort to occlude tertiary and quaternary branches of the renal artery as close to pseudo aneurysmal pocket as possible in order to limit collateral damage to viable, healthy renal tissue. MSKCC investigators reported 1,461 PN performed from 2003–2010. There were 15 pseudo aneurysms (1%) including 7/1,160 (0.6%) in open PN and 8/301 (2.6%) minimally invasive PN. Fourteen of fifteen patients were successfully treated with embolization but one patient with a coagulopathy required a completion RN [91].

FOLLOW-UP AFTER PARTIAL NEPHRECTOMY FOR CLINICALLY LOCALIZED RENAL NEOPLASMS

In an attempt to standardize the follow-up after nephrectomy, the AUA recently published guidelines based on tumor stage. All patients should undergo interval history and physical examination and laboratory testing including blood urea nitrogen/creatinine, urinalysis and eGFR. Low-risk patients (pT1, N0, Nx) should undergo a baseline abdominal scan (CT or MRI) within 3–12 months following surgery. If the initial scan is negative, abdominal imaging to assess for pulmonary metastases for 3 years, and if clinically indicated beyond that period. Moderate to high risk patients (pT2–4N0 or any N+ stage) should undergo baseline chest and abdominal scans (CT or MRI) within 3–6 months following surgery, with continued imaging every 6 months for 3 years at least, and annually thereafter to year 5. Imaging beyond 5 years may be performed at the discretion of the clinician [92]. At MSKCC, after two years without evidence of disease recurrence, we refer patients to our "survivorship" clinic where long term renal cancer follow-up, general medical care, and oncological screening is provided. As much as possible, renal US and chest x-ray are utilized in follow-up unless specific patient signs or symptoms need to be directly addressed.

CONCLUSIONS

PN is an essential operation for the management of small renal masses increasingly detected by cross sectional imaging usually obtained for the evaluation of nonspecific abdominal or musculoskeletal complaints. With the median size of < 4 cm, PN provides equivalent oncological control for the T1 tumor as does RN while at the same time preventing or delaying CKD and its potential for late cardiovascular morbidity and mortality. This kidney functional preserving effect is amplified by the fact that approximately 45% of patients will have a benign or indolent tumor resected with little or no metastatic potential. Open PN using a mini-flank supra 11th rib approach is a highly effective operation that should be part of every renal surgeon’s arsenal. This approach provides rapid exposure to the kidney is useful for both straightforward and complex operations, is cost effective, and now associated with a surgical length of stay 2.6 days. Potential complications of postoperative bleeding, infection, and urinary fistula can occur but most are managed with conservative measures that ultimately preserve the kidney. The mini-flank approach can readily be taught to residents and fellows and can potentially increase the pool of patients worldwide that can undergo a kidney sparing operation.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Beare JB, McDonald JR. Involvement of the renal capsule in surgically removed hyper-nephroma; a gross and histopathologic study. J Urol 1949;61:857-61.
2. Mortensen H. Transthoracic nephrectomy. J Urol 1948;60:855-8.
3. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol 1963;89:37-42.
4. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
5. Skinner DG, Colvin RB, Vermillion CD, Pfizer RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
6. Patel NP, Lavengood RW. Renal cell carcinoma: natural history and results of treatment. J Urol 1978;119:722-6.
7. Sagalowsky AJ, Kadesky KT, Ewalt DM, Kennedy TJ. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994;151:1181-4.
8. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991;146:1224-7.
9. Ditonno P, Traficante A, Battaglia M, Grossi PS, Selvaggi FP. Role of lymphadenectomy in renal cell carcinoma. Prog Clin Biol Res 1992;378:169-74.
10. Robson CJ. Results of radical thoraco-abdominal nephrectomy in the treatment of renal cell carcinoma. Prog Clin Biol Res 1982;100:481-8.

11. Russo P. Open radical nephrectomy for localized renal cell carcinoma. In: Vogelzang, Nicholas J. Genitourinary oncology. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 725-31.

12. Herr HW. A history of partial nephrectomy for renal tumors. J Urol 2005;173:705-8.

13. Herr HW. Surgical management of renal tumors: a historical perspective. Urol Clin North Am 2008;35:543-9; v.

14. Boyce WH, Elkins IB. Reconstructive renal surgery following anatrophic nephrolithotomy: followup of 100 consecutive cases. J Urol 1974;111:307-12.

15. Brodel M. The intrinsic blood vessels of the kidney and their significance in nephroptomy. Johns Hopkins Hosp Bull 1901;12:10-3.

16. Woodhouse CR, Farrell CR, Paris AM, Blandy JP. The place of extended pyelolithotomy (Gil-Vernet Operation) in the management of renal staghorn calculi. Br J Urol 1981;53:520-3.

17. McAninch JW, Carroll PR. Renal exploration after trauma. Indications and reconstructive techniques. Urol Clin North Am 1989;16:203-12.

18. Russo P. The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 2011;25:737-52.

19. Licht MR, Novick AC. Nephron sparing surgery for renal cell carcinoma. J Urol 1993;149:1-7.

20. Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol 1999;161:33-4.

21. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000;163:442-5.

22. Gilbert BR, Russo P, Zirinsky K, Kazam E, Fair WR, Vaughan ED Jr. Intraoperative sonography: application in renal cell carcinoma. J Urol 1988;139:582-4.

23. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001;166:6-18.

24. Russo P, Huang W. The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. Urol Clin North Am 2008;35:635-43.

25. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol 2000;163:730-6.

26. Lesage K, Joniau S, Fransia K, Van Poppel H. Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life. Eur Urol 2007;51:614-20.

27. Russo P, Goetzl M, Simmons R, Katz J, Motzer R, Reuter V. Partial nephrectomy: the rationale for expanding the indications. Ann Surg Oncol 2002;9:680-7.

28. Leibovich BC, Blute ML, Cheville JC, Louis CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066-70.

29. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006;97:939-45.

30. Pahernik S, Roos P, Rohrig B, Wiesner C, Thuroff JW. Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2008;179:71-4.

31. Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML. Partial versus radical nephrectopy for 4 to 7 cm renal cortical tumors. J Urol 2009;182:2601-6.

32. Karelis ME, O’Brien MF, Jang TL, Bernstein M, Russo P. Partial nephrectomy for selected renal cortals of ≥ 7 cm. BJU Int 2010;106:1484-7.

33. Breau RH, Crispin PL, Jimenez RE, Lohse CM, Blute ML, Leibovich BC. Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol 2010;183:903-8.

34. Segev DL, Mazzola AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010;303:599-66.

35. Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation 2001;72:444-9.

36. Goldfarb DA, Matin SF, Braun WE, Schreiber MJ, Mastroianni B, Papajick D, et al. Renal outcome 25 years after donor nephrectomy. J Urol 2001;166:2043-7.

37. Kaplan C, Fasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975;80:227-34.

38. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236-42.

39. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002;59:816-20.

40. Sarnak MJ, Levey AS, Schoenfeld DS, Coresh J, Caffo BS, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.

41. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.

42. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.

43. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.

44. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-40.

45. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468-71.

46. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P, Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes? J Urol 2009;181:55-61.

47. Tan HH, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012;307:1629-35.

48. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: Korean J Urol 2014;55:557-567.
49. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-9.

50. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology 2006;67:254-9.

51. Miller DC, Hollingsworth JM, Hafez KS, Daigault S, Hollenbeck BK. Partial nephrectomy for small renal masses: an emerging quality of care concern? J Urol 2006;175(3 Pt 1):853-7.

52. Dulanon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer 2010;116:2316-21.

53. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal cell carcinoma: a systematic review and meta-analysis. J Urol 2012;188:51-7.

54. Kopka L, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe RR, et al. EAU guidelines on renal cell carcinoma: 2010 update. Eur Urol 2010;58:398-406.

55. Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2010;116:2316-21.

56. Cattau EL, DeLellis RA, Eble JN, Eusebi V, Enzinger FM, et al. World Health Organization classification of tumors: soft tissue and bone tumors. 3rd ed. Lyon, France: IARC Press; 2002.

57. Galvin DJ, Savage CJ, Adamy A, Kaag M, O’Brien MF, Kallingal JK, et al. Rationale for percutaneous biopsy and histologic characterization of renal tumours. Eur Urol 2012;62:491-504.

58. Raj GV, Thompson RH, Kattan MW, et al. Developments in the surgical management of sporadic synchronous bilateral renal tumours. BJU Int 2010;105:1093-7.

59. Coleman JA, Russo P. Hereditary and familial kidney cancer. Curr Opin Urol 2009;19:478-85.

60. Richstone L, Scherr DS, Reuter VR, Snyder ME, Rabbani F, Kattan MW, et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol 2004;171(2 Pt 1):615-20.

61. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson LM, et al. Impact of a common clinical pathway on length of hospital stay and role of active surveillance. Urol Clin North Am 2010;37:311-26.

62. Krupski TC, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116:3119-26.

63. Chatterjee S, Nam R, Fleshner N, Klotz L. Permanent flank bulge is a consequence of flank incision for radical nephrectomy in one half of patients. Urol Oncol 2004;22:36-9.

64. Diblasio CJ, Snyder ME, Russo P. Mini-flank supra-11th rib incision for open partial or radical nephrectomy. BJU Int 2006;97:149-56.

65. Huang WC, Kagiwada MA, Russo P. Surgery insight: advances in techniques for open partial nephrectomy. Nat Clin Pract Urol 2007;4:444-50.

66. Tarin T, Feifer A, Kimm S, Chen L, Sjoberg D, Coleman J, et al. Impact of a common clinical pathway on length of hospital stay in patients undergoing open and minimally invasive kidney surgery. J Urol 2014;191:1225-30.

67. Patel MI, Simmons R, Kattan MW, Motzer RJ, Reuter VE, Russo P. Long-term follow-up of bilateral sporadic renal tumors. Urology 2003;61:921-5.

68. Lowrance WT, Yee DS, Maschino AC, Cronin AM, Bernstein M, Thompson RH, et al. Developments in the surgical management of sporadic synchronous bilateral renal tumours. BJU Int 2010;105:1093-7.

69. Coleman JA, Russo P. Hereditary and familial kidney cancer. Curr Opin Urol 2009;19:478-85.

70. Richstone L, Scherr DS, Reuter VR, Snyder ME, Rabbani F, Kattan MW, et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol 2004;171(2 Pt 1):615-20.

71. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A post-operative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-7.

72. Adamy A, Lowrance WT, Yee DS, Chong KT, Bernstein M, Tickoo SK, et al. Renal oncycosis: management and clinical outcomes. J Urol 2011;185:785-90.

73. Lane BR, Russo P, Uzzo RG, Hernandez AV, Boorjian SA, Thompson RH, et al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol 2011;185:421-7.

74. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 2008;179:2158-63.

75. Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, Blute ML. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol 2002;168:454-9.

76. Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P. Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience. BJU Int 2004;94:1323-8.

77. Ching CB, Lane BR, Campbell SC, Li J, Fergany AF. Five to 10-year followup of open partial nephrectomy in a solitary kidney. J Urol 2013;190:470-4.

78. Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, et al. Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases. J Urol 2011;185:37-42.

79. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009;182:854-9.

80. Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008;179:2146-51.

81. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009;182:844-53.

82. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116:3119-26.

83. Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, et al. Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases. J Urol 2011;185:37-42.

84. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009;182:854-9.

85. Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008;179:89-93.

86. Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, et al. Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol 2008;180:104-9.

87. Galvin DJ, Savage CJ, Adamy A, Kaag M, O’Brien MF, Kallingal G, et al. Intraperative conversion from partial to radical nephrectomy at a single institution from 2003 to 2008. J Urol 2011;185:1204-9.

88. Patel MI, Simmons R, Kattan MW, Motzer RJ, Reuter VE, Russo P. Long-term follow-up of bilateral sporadic renal tumors. Urology 2003;61:921-5.
86. Stephenson AJ, Hakimi AA, Snyder ME, Russo P. Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 2004;171:130-4.
87. Meeks JJ, Zhao LC, Navai N, Perry KT Jr, Nadler RB, Smith ND. Risk factors and management of urine leaks after partial nephrectomy. J Urol 2008;180:2375-8.
88. Kundu SD, Thompson RH, Kallingal GJ, Cambareri G, Russo P. Urinary fistulae after partial nephrectomy. BJU Int 2010;106:1042-4.
89. Sanchez-Ortiz R, Madsen LT, Swanson DA, Canfield SE, Wood CG. Closed suction or penrose drainage after partial nephrectomy: does it matter? J Urol 2004;171:244-6.
90. Godoy G, Katz DJ, Adamy A, Jamal JE, Bernstein M, Russo P. Routine drain placement after partial nephrectomy is not always necessary. J Urol 2011;186:411-5.
91. Ghoneim TP, Thornton RH, Solomon SB, Adamy A, Favaretto RL, Russo P. Selective arterial embolization for pseudoaneurysms and arteriovenous fistula of renal artery branches following partial nephrectomy. J Urol 2011;185:2061-5.
92. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol 2013;190:407-16.